申请人:Pfizer Inc.
公开号:US05837711A1
公开(公告)日:1998-11-17
Certain novel substituted quinuclidine compounds having the ability to antagonize substance P and having the following formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; X is --CONR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CH.sub.2 OR.sup.3, --CH.sub.2 NR.sup.3 R.sup.4 or --CONR.sup.3 OR.sup.4 ; R.sup.1, R.sup.3 and R.sup.4 are each, independently, hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 is alkyl having 1 to 4 carbon atoms; Y is alkylsulfonyl having 1 to 4 carbon atoms, N-alkyl-N-alkanoylamino (which may be substituted by halogen in the alkanoyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkanoyl moieties, N-alkyl-N-alkylsulfonylamino (which may be substituted by halogen in the alkylsulfonyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkyl sulfonyl moieties, alkenyl having 2 to 4 carbon atoms, alkynyl having 2 to 4 carbon atoms, halosubstituted alkyl having 1 to 4 carbon atoms, alkylamino having 1 to 4 carbon atoms, alkanoylamino (which may be substituted by halogen) having 1 to 4 carbon atoms or alkylsulfonylamino (which may be substituted by halogen) having 1 to 4 carbon atoms. These compounds are useful in the treatment gastrointestinal or central nervous system disorders and the alleviation of inflammatory diseases, asthma, pain and migraine in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
具有拮抗物质P能力的某些新型取代的喹诺啡啶化合物,其化学式如下:##STR1## 其中Ar.sup.1和Ar.sup.2分别独立地为噻吩基、苯基、氟苯基、氯苯基或溴苯基;X为--CONR.sup.3 R.sup.4、--CO.sub.2R.sup.3、--CH.sub.2OR.sup.3、--CH.sub.2NR.sup.3 R.sup.4或--CONR.sup.3 OR.sup.4;R.sup.1、R.sup.3和R.sup.4分别独立地为氢或1至4个碳原子的烷基;R.sup.2为1至4个碳原子的烷基;Y为1至4个碳原子的烷基磺酰基、N-烷基-N-烷酰胺基(在烷酰基中可能被卤素取代),在烷基和酰基中分别含有1至4个碳原子、N-烷基-N-烷基磺酰胺基(在烷基磺酰基中可能被卤素取代),在烷基和烷基磺酰基中分别含有1至4个碳原子、2至4个碳原子的烯基、2至4个碳原子的炔基、1至4个碳原子的卤代烷基、1至4个碳原子的烷基氨基、1至4个碳原子的酰胺基(可能被卤素取代)或1至4个碳原子的烷基磺酰胺基(可能被卤素取代)。这些化合物可用于治疗哺乳动物的胃肠或中枢神经系统疾病,缓解炎症性疾病、哮喘、疼痛和偏头痛,并作为治疗这些疾病的制药组合物的活性成分。